MR-vejledt laserablation til behandling af hjernetumorer og epilepsi
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
MR-vejledt laserablation til behandling af hjernetumorer og epilepsi. / Nielsen, Silas Haahr; Ziebell, Morten; Hansen, Adam Espe; Skjøth-Rasmussen, Jane; von Oettingen, Gorm B; Pinborg, Lars Hageman; Jespersen, Bo; Møller, Søren; Rasmussen, Rune.
In: Ugeskrift for Laeger, Vol. 183, V02210128, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - MR-vejledt laserablation til behandling af hjernetumorer og epilepsi
AU - Nielsen, Silas Haahr
AU - Ziebell, Morten
AU - Hansen, Adam Espe
AU - Skjøth-Rasmussen, Jane
AU - von Oettingen, Gorm B
AU - Pinborg, Lars Hageman
AU - Jespersen, Bo
AU - Møller, Søren
AU - Rasmussen, Rune
N1 - Publisher Copyright: © 2021,Ugeskrift for Laeger.All Rights Reserved
PY - 2021
Y1 - 2021
N2 - MR-guided laser interstitial thermal therapy (LITT) is a minimally invasive neurosurgical procedure, which in the last decade has gained significant momentum of the treatment of intracranial tumours and epileptic foci. In brief, LITT utilises the heat from a stereotactically placed laser catheter to selectively ablate a lesion or a structure under real-time MRI guidance, which is summarised and discussed in this review. The first LITT system gained FDA approval in 2007 and was CE-marked in 2018. In December 2020, the first patient with recurrent glioblastoma was treated at the Department of Neurosurgery at Rigshospitalet, Copenhagen.
AB - MR-guided laser interstitial thermal therapy (LITT) is a minimally invasive neurosurgical procedure, which in the last decade has gained significant momentum of the treatment of intracranial tumours and epileptic foci. In brief, LITT utilises the heat from a stereotactically placed laser catheter to selectively ablate a lesion or a structure under real-time MRI guidance, which is summarised and discussed in this review. The first LITT system gained FDA approval in 2007 and was CE-marked in 2018. In December 2020, the first patient with recurrent glioblastoma was treated at the Department of Neurosurgery at Rigshospitalet, Copenhagen.
KW - Brain Neoplasms/diagnostic imaging
KW - Epilepsy/surgery
KW - Humans
KW - Laser Therapy
KW - Lasers
KW - Magnetic Resonance Imaging
KW - Neoplasm Recurrence, Local/surgery
M3 - Tidsskriftartikel
C2 - 34169824
VL - 183
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
M1 - V02210128
ER -
ID: 288282256